Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Pravachol vs. Lipitor Update

    In my March 11 piece below, I mentioned the possibility of Pravachol competing on price with Lipitor. But over at Forbes, Matthew Herper has pointed out that it’s currently more expensive. What BMS is going to do with this drug, I can’t imagine. There’s also a good story in the Newark Star-Ledger about the whole… Read More
  • Birth of an Idea

    Mismatched Socks

    Some miscellaneous updates tonight, in addition to the note appended to the post below. It seems that Sunday nights don’t often leave with time for more extensive blogging, and the world events of the last few days have made their claim on my attention as well. This isn’t going to be one of those dull… Read More
  • Business and Markets

    Ignorance Was Bliss

    Just a brief note today about the “PROVE-IT” study that Bristol-Meyers Squibb ran and has now reported on. This was their big shot at Pfizer’s Lipitor, their chance to show that their own statin, Pravachor, was just as good or better. The study was big, it was long, and man, was it expensive. It’s just… Read More
  • Business and Markets

    I will do such things – What they are yet I know not. . .

    Igor Landau of Aventis must have been seen a performance of King Lear recently, to judge from his tactics to fend off Sanofi’s hostile takeover bid. Or since the following also has a “Do you feel lucky?” ring to it, maybe they’ve been watching old Clint Eastwood movies instead. Surely those have been dubbed into… Read More
  • Business and Markets

    Allons Pharmas de la Patrie!

    So Sanofi-Synthelabo is making a bid for Aventis. Shows you what I know about this business – if I’d guessed that this was in the works, which I didn’t, I’d have bet that it would have been the other way around. Aventis would seem to be the company more in need of help. But as… Read More
  • Business and Markets

    . . .Your Huddled Pharmas Yearning to Breath Free

    Genetic Engineering News reprints parts of a speech given by Rolf Krebs, chairman of the German drug firm Boehringer Ingleheim, at a recent conference in Hannover. Dr. Krebs was speaking on the differences in pharma research between Europe and America, and he didn’t leave much bottled up: “The framework conditions for the pharmaceutical… Read More
  • Business and Markets

    Ah, Marketing

    The Advertising column in today’s Wall St. Journal has an interesting note on some recent Merck ads for their COX-2 inhibitor, Vioxx. What they’ve done is break their TV ads up into pieces. Why would you do that? Well, the FDA rules are that if you mention a drug and what it’s good for in… Read More
  • Business and Markets

    Mismeasure for Mismeasure

    While I’m on the subject, there’s another problem with employee rankings, one that doesn’t just apply to research organizations. I first came across a statement of it while reading Bill James, who showed how it applies to baseball teams when they decide whether to bring in some veteran player to hold down a position or… Read More
  • Business and Markets

    Measure for Measure

    As a follow-up to my post about over-quantification, I should really mention one of the things that managers in research organizations would most love to measure: their employees. How good are they? How productive are they? How do they rank, from one to thirty-eight? The problem is, there’s no good way to measure any of… Read More
  • Business and Markets

    What Sort of Number Did You Have in Mind?

    There’s a good article by Leandro Herrero in the October issue of Scrip magazine (no online content without a subscription.) He’s teeing off on the overuse of numerical measures in the drug industry (and industry in general:) “Your business education and experience tell you that if you can’t measure, you can’t manage.… Read More